查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1590811

胃食道逆流疾病治療藥物市場：按類型、藥物類別、應用分類 - 全球預測 2025-2030

Gastroesophageal Reflux Disease Therapeutics Market by Type (Branded, Generics), Drug Class (Aminosalicylates, Anti-Diarrheal, Anti-Emetics), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年胃食道逆流症治療市值為58.5億美元，預計2024年將達61.4億美元，複合年成長率為5.01%，到2030年將達到82.4億美元，預計將達到1000萬美元。

胃食道逆流症 (GERD) 治療藥物市場重點在於可用於治療 GERD 的治療方案，GERD 是一種慢性消化系統疾病，胃酸和膽汁會刺激食道內壁。這項市場需求是由肥胖、飲酒增加、吸煙和老齡化等生活方式因素導致的胃食道逆流的流行所推動的，這些因素共同推動了對有效治療性介入的需求。這些治療應用包括質子幫浦阻斷劑、H2 受體拮抗劑、制酸劑和促動力藥，每種藥物都針對不同的機制來緩解 GERD 症狀。最終用途包括醫院、專科診所和居家醫療，促進治療方法的廣泛採用。就市場洞察而言，醫療保健支出的增加、對胃食道逆流的認知不斷提高以及藥物開發的進步是推動成長的關鍵因素。此外，新型藥物輸送系統和個人化醫療方法的引入也帶來了潛在的商機。儘管有這些正面影響，但市場仍面臨挑戰，例如嚴格的監管核准、高昂的治療成本以及與長期使用某些藥物相關的副作用。微創手術、生物分解性支架和以患者為中心的行動醫療應用等領域的創新有可能進一步改善結果。此外，探索益生菌和營養食品作為補充治療方法可以提供新的收益來源。 GERD 治療市場呈現出不斷變化的形勢，由於全球消費者意識的不斷增強和醫療保健投資的增加，該市場有望實現成長。企業應專注於擴大研發活動並建立策略夥伴關係關係，以解決未滿足的需求並提高競爭力。然而，也必須考慮遵守嚴格監管標準和提高可及性的經濟有效的策略。為了抓住這個充滿活力的行業的新機遇，保持對消費者趨勢和技術進步的敏感度非常重要。

主要市場統計
基準年[2023] 58.5億美元
預測年份 [2024] 61.4億美元
預測年份 [2030] 82.4億美元
複合年成長率（%） 5.01%

市場動態：揭示快速發展的胃食道逆流藥物市場的關鍵市場洞察

胃食道逆流藥物市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 胃食道逆流患者病率上升
    • 建立不健康的生活方式和飲食習慣
    • 質子幫浦抑制劑的使用增加
  • 市場限制因素
    • 與 GERD 藥物相關的副作用
  • 市場機會
    • 藥廠加大研發投入
    • GERD治療器械在微創手術中的普及
  • 市場挑戰
    • 自然療法的替代品

波特五力：駕馭胃食道逆流藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解胃食道逆流藥物市場的外部影響

外部宏觀環境因素在塑造胃食道逆流疾病治療藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解胃食道逆流症治療藥物市場的競爭狀況

對胃食道逆流症治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣胃食道逆流藥物市場供應商的績效評估

FPNV定位矩陣是評估胃食道逆流症治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪胃食道逆流症治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對胃食道逆流症治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 胃食道逆流患者病率增加
      • 採取不健康的生活方式和飲食習慣
      • 質子幫浦阻斷劑的使用增加
    • 抑制因素
      • 與胃食道逆流藥物相關的副作用
    • 機會
      • 藥廠加大研發投入
      • GERD 裝置在微創手術中變得流行
    • 任務
      • 自然療法的替代品
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章胃食道逆流症治療藥物市場：依類型

  • 品牌
  • 非專利的

第7章依藥物類別分類的胃食道逆流症治療藥物市場

  • 氨基胺基
  • 止瀉
  • 止吐藥
  • 生技藥品/生物相似藥
  • 消化酵素
  • H2拮抗劑
  • 瀉藥
  • 質子幫浦抑制劑

第8章胃食道逆流症治療藥物市場：依應用分類

  • 克隆氏症
  • 胃食道逆流症
  • 潰瘍性大腸炎

第9章北美及南美胃食道逆流症治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太胃食道逆流症治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲胃食道逆流症治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
  • 戰略分析和建議

公司名單

  • Aurobindo Pharma Limited
  • Cadila Pharmaceuticals Limited
  • CHEPLAPHARM Arzneimittel GmbH
  • Daewoong Pharmaceutical Co., Ltd
  • Eisai Co., Ltd.
  • EndoStim, Inc.
  • GlaxoSmithKline PLC
  • Jeil Pharmaceutical Co., Ltd.
  • Novartis AG
  • Reckitt Benckiser Group PLC
  • SFJ Pharmaceuticals Group
  • SRS Life Sciences Pte. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceuticals Industries Limited
Product Code: MRR-AD36CD897D13

The Gastroesophageal Reflux Disease Therapeutics Market was valued at USD 5.85 billion in 2023, expected to reach USD 6.14 billion in 2024, and is projected to grow at a CAGR of 5.01%, to USD 8.24 billion by 2030.

The Gastroesophageal Reflux Disease (GERD) Therapeutics market focuses on the treatment options available for managing GERD, a chronic digestive disorder where stomach acid or bile irritates the food pipe lining. The necessity of this market stems from the prevalence of GERD due to lifestyle factors like obesity, increased consumption of alcohol, smoking, and aging, which collectively increase the demand for effective therapeutic interventions. The application of these therapeutics spans proton pump inhibitors, H2 receptor antagonists, antacids, and prokinetics, each targeting different mechanisms to alleviate GERD symptoms. End-use segments include hospitals, specialty clinics, and homecare settings, facilitating widespread availability of treatments. As for market insights, rising healthcare expenditure, increased awareness about GERD, and advancements in drug development are key factors driving growth. Additionally, the incorporation of novel drug delivery systems and personalized medicine approaches present potential opportunities. Despite these positive influences, the market faces challenges such as stringent regulatory approvals, high treatment costs, and the side effects associated with long-term use of certain medications. Innovating in areas like minimally invasive surgical procedures, biodegradable stents, and patient-centric mobile health applications could further enhance therapeutic outcomes. Additionally, exploring probiotics and dietary supplements as complementary treatments can provide new revenue streams. The GERD therapeutics market showcases an evolving landscape poised for growth as consumer awareness and investment in healthcare rise globally. Companies should focus on expanding their R&D activities and forming strategic partnerships to address unmet needs and enhance their competitive edge. However, they must also navigate compliance with stringent regulatory standards and consider cost-effective strategies to increase accessibility. With its dynamic nature, staying attuned to consumer trends and technological advancements will be crucial for capturing emerging opportunities in this sector.

KEY MARKET STATISTICS
Base Year [2023] USD 5.85 billion
Estimated Year [2024] USD 6.14 billion
Forecast Year [2030] USD 8.24 billion
CAGR (%) 5.01%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gastroesophageal Reflux Disease Therapeutics Market

The Gastroesophageal Reflux Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of gastroesophageal reflux diseases
    • Adoption of unhealthy lifestyle and eating habits
    • Increasing use of proton pump inhibitors
  • Market Restraints
    • Side effects related to the drugs of GERD
  • Market Opportunities
    • Increasing investment by pharma companies in R&D
    • GERD devices gaining traction for minimally invasive procedures
  • Market Challenges
    • Alternatives of natural remedies

Porter's Five Forces: A Strategic Tool for Navigating the Gastroesophageal Reflux Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gastroesophageal Reflux Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gastroesophageal Reflux Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gastroesophageal Reflux Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gastroesophageal Reflux Disease Therapeutics Market

A detailed market share analysis in the Gastroesophageal Reflux Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gastroesophageal Reflux Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gastroesophageal Reflux Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gastroesophageal Reflux Disease Therapeutics Market

A strategic analysis of the Gastroesophageal Reflux Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastroesophageal Reflux Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co., Ltd, Eisai Co., Ltd., EndoStim, Inc., GlaxoSmithKline PLC, Jeil Pharmaceutical Co., Ltd., Novartis AG, Reckitt Benckiser Group PLC, SFJ Pharmaceuticals Group, SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceuticals Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Gastroesophageal Reflux Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Branded and Generics.
  • Based on Drug Class, market is studied across Aminosalicylates, Anti-Diarrheal, Anti-Emetics, Biologics/Biosimilar, Digestive enzymes, H2 Antagonists, Laxatives, and Proton Pump Inhibitors.
  • Based on Application, market is studied across Crohn's Disease, GERD, and Ulcerative Colitis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of gastroesophageal reflux diseases
      • 5.1.1.2. Adoption of unhealthy lifestyle and eating habits
      • 5.1.1.3. Increasing use of proton pump inhibitors
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects related to the drugs of GERD
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment by pharma companies in R&D
      • 5.1.3.2. GERD devices gaining traction for minimally invasive procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Alternatives of natural remedies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gastroesophageal Reflux Disease Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Branded
  • 6.3. Generics

7. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Aminosalicylates
  • 7.3. Anti-Diarrheal
  • 7.4. Anti-Emetics
  • 7.5. Biologics/Biosimilar
  • 7.6. Digestive enzymes
  • 7.7. H2 Antagonists
  • 7.8. Laxatives
  • 7.9. Proton Pump Inhibitors

8. Gastroesophageal Reflux Disease Therapeutics Market, by Application

  • 8.1. Introduction
  • 8.2. Crohn's Disease
  • 8.3. GERD
  • 8.4. Ulcerative Colitis

9. Americas Gastroesophageal Reflux Disease Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gastroesophageal Reflux Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aurobindo Pharma Limited
  • 2. Cadila Pharmaceuticals Limited
  • 3. CHEPLAPHARM Arzneimittel GmbH
  • 4. Daewoong Pharmaceutical Co., Ltd
  • 5. Eisai Co., Ltd.
  • 6. EndoStim, Inc.
  • 7. GlaxoSmithKline PLC
  • 8. Jeil Pharmaceutical Co., Ltd.
  • 9. Novartis AG
  • 10. Reckitt Benckiser Group PLC
  • 11. SFJ Pharmaceuticals Group
  • 12. SRS Life Sciences Pte. Ltd.
  • 13. Sun Pharmaceutical Industries Limited
  • 14. Takeda Pharmaceutical Co., Ltd.
  • 15. Teva Pharmaceuticals Industries Limited

LIST OF FIGURES

  • FIGURE 1. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTI-DIARRHEAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTI-EMETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS/BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DIGESTIVE ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GERD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023